ALX Oncology(ALXO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., August 8, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our team continues to make significant progress in the advance ...